Share count
27Mpeak FY2025
← All companies ← ARCB Manual ARDT → ← AQST Pharmaceuticals ARDX →
ARCT, Arcturus Therapeutics Holdings Inc.
We are a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics.
We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based therapeutics for rare genetic disorders with significant unmet medical needs and vaccines for infectious diseases.
We have extensive expertise in the design and optimization of mRNA constructs, including with respect to a type of mRNA technology known as self-amplifying mRNA (sa-mRNA).
The business
What it sells, where the money comes from, the kind of company it is.
Revenue · FY2025
$82M
−46.1% YoY · 54% 5-yr CAGR
Vital signs · TTM
Cash & investments $211M
Cash burn · annual $59M
Runway 3.6 yrs
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
- What moves the needle
- Operating margin has run around −123% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 21% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2018–2025
realized figures from each filing · older years to the left| 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| $16M | $21M | $10M | $12M | $206M | $167M | $152M | $82M | $55M | RevenueRevenue |
| 131% | 61% | 243% | 335% | 22% | 32% | 35% | 56% | 81% | SG&A / revenueSG&A/rev |
| 108% | 162% | 606% | n/m | 72% | 115% | 128% | 137% | 181% | R&D / revenueR&D/rev |
| ($22M) | ($26M) | ($72M) | ($203M) | $12M | ($78M) | ($96M) | ($76M) | ($88M) | Operating incomeOp. inc. |
| −138.5% | −122.7% | −749.8% | n/m | 5.9% | −46.9% | −62.8% | −93.0% | −161.5% | Operating marginOp. mgn |
| ($22M) | ($26M) | ($72M) | ($204M) | $9M | ($30M) | ($81M) | ($66M) | ($79M) | Net incomeNet inc. |
| Cash flow & returns | |||||||||
| ($21M) | ($6M) | ($43M) | ($135M) | $32M | ($18M) | ($60M) | ($74M) | ($59M) | Operating cash flowOp. cash |
| $582K | $684K | $882K | $1M | $2M | $3M | $4M | $3M | $3M | DepreciationDeprec. |
| ($816K) | $17M | $22M | $39M | ($9M) | ($26M) | ($20M) | ($37M) | ($6M) | Working capital & otherWC & other |
| $1M | $818K | $2M | $3M | $8M | $3M | $648K | $230K | $93K | CapexCapex |
| 9.4% | 3.9% | 18.3% | 27.6% | 3.8% | 1.7% | 0.4% | 0.3% | 0.2% | Capex / revenueCapex/rev |
| ($21M) | ($7M) | ($44M) | ($136M) | $30M | ($21M) | ($60M) | ($75M) | ($59M) | Owner earningsOwner earn. |
| −135.5% | −34.9% | −458.6% | n/m | 14.8% | −12.6% | −39.7% | −90.8% | −107.2% | Owner earnings marginOE mgn |
| ($22M) | ($7M) | ($45M) | ($138M) | $24M | ($21M) | ($60M) | ($75M) | ($59M) | Free cash flowFCF |
| −141.2% | −34.9% | −467.6% | n/m | 11.8% | −12.6% | −39.7% | −90.8% | −107.2% | Free cash flow marginFCF mgn |
| -160% | -101% | -18% | -89% | 3% | -11% | -34% | -31% | -41% | Return on equityROE |
| −160% | −101% | −18% | −89% | 3% | −11% | −34% | −31% | −41% | Retained to equityRetained/eq |
| Balance sheet | |||||||||
| $37M | $71M | $463M | $370M | $392M | $292M | $237M | $231M | $211M | Cash & investmentsCash+inv |
| $4M | $2M | $2M | $3M | $3M | $32M | $4M | $6M | $1M | ReceivablesReceiv. |
| $2M | $6M | $11M | $10M | $7M | $5M | $7M | $4M | $4M | Accounts payablePayables |
| $2M | ($4M) | ($9M) | ($7M) | ($5M) | $27M | ($3M) | $1M | ($3M) | Operating working capitalOper. WC |
| $42M | $74M | $468M | $379M | $403M | $387M | $306M | $241M | $217M | Current assetsCur. assets |
| $13M | $21M | $50M | $100M | $127M | $82M | $65M | $36M | $34M | Current liabilitiesCur. liab. |
| 3.3× | 3.5× | 9.4× | 3.8× | 3.2× | 4.7× | 4.7× | 6.6× | 6.3× | Current ratioCurr. ratio |
| $44M | $82M | $476M | $393M | $450M | $429M | $344M | $271M | $245M | Total assetsAssets |
| $10M | $15M | $15M | $63M | $61M | — | — | — | $76M | Total debtDebt |
| ($27M) | ($56M) | ($448M) | ($307M) | ($331M) | — | — | — | ($136M) | Net debt / (cash)Net debt |
| $14M | $26M | $397M | $228M | $270M | $279M | $241M | $214M | $191M | Shareholders’ equityEquity |
| 8.0% | 9.5% | 70.9% | 234.0% | 14.9% | 20.8% | 24.9% | 31.0% | 42.2% | Stock comp / revenueSBC/rev |
| Per share | |||||||||
| 10.1M | 12.1M | 20.3M | 26.3M | 27.1M | 26.6M | 27.0M | 27.4M | 28.4M | Shares out (diluted)Shares |
| $1.56 | $1.72 | $0.47 | $0.47 | $7.60 | $6.26 | $5.64 | $3.00 | $1.92 | Revenue / shareRev/sh |
| $-2.16 | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3.00 | $-2.40 | $-2.77 | EPS (diluted)EPS |
| $-2.12 | $-0.60 | $-2.15 | $-5.18 | $1.12 | $-0.79 | $-2.24 | $-2.72 | $-2.06 | Owner earnings / shareOE/sh |
| $-2.21 | $-0.60 | $-2.20 | $-5.26 | $0.90 | $-0.79 | $-2.24 | $-2.72 | $-2.06 | Free cash flow / shareFCF/sh |
| $0.15 | $0.07 | $0.09 | $0.13 | $0.29 | $0.11 | $0.02 | $0.01 | $0.00 | Cap. spending / shareCapex/sh |
| $1.35 | $2.14 | $19.53 | $8.67 | $9.98 | $10.46 | $8.93 | $7.81 | $6.73 | Book value / shareBVPS |
The diluted share count moved ×1.68 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
Per-share growththe realized rate an owner's share compounded
| 7-yr | 5-yr | |
|---|---|---|
| Revenue / share | +9.7%/yr | +44.8%/yr |
| Capital spending / share | −33.5%/yr | −37.2%/yr |
| Book value / share | +28.4%/yr | −16.7%/yr |
The record, charted
FY2018–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
($75M)owner earningsvs.($66M)net incomelow FY2021
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business reported a $66M loss but ($75M) of owner earnings: $9M less than the profit line, taken out by capital spending and the timing of cash.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | ($66M) | ($81M) | ($30M) | $9M | ($204M) |
| Depreciation & amortizationnon-cash charge added back | +$3M | +$4M | +$3M | +$2M | +$1M |
| Stock-based compensationreal costnon-cash, but a real cost | +$25M | +$38M | +$35M | +$31M | +$29M |
| Working capital & othertiming of cash in and out, other non-cash items | −$37M | −$20M | −$26M | −$9M | +$39M |
| Cash from operations | ($74M) | ($60M) | ($18M) | $32M | ($135M) |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −$230K | −$648K | −$3M | −$2M | −$1M |
| Owner earnings | ($75M) | ($60M) | ($21M) | $30M | ($136M) |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | — | — | −$6M | −$2M |
| Free cash flow | ($75M) | ($60M) | ($21M) | $24M | ($138M) |
| Owner-earnings marginowner earnings ÷ revenue | -91% | -40% | -13% | 15% | -1102% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $25M), owner earnings is nearer ($100M).
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
FY2025 10-K · source on SEC EDGAR →
Will it survive?
- No meaningful interest burdenLittle or no interest expense reported
What this means
Little or no interest expense reported, the business isn't leaning on lenders to operate.
- Net cashCash $231M − debt $101M
What this means
Cash and short-term investments exceed every dollar of debt by $130M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Below averageNOPAT ($60M) ÷ invested capital $84M (debt + equity − cash)Industry peers: median -70%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Consumes cash through the cycle8-yr median margin, range -1102%–15%; latest ($75M) = operating cash ($74M) − maintenance capex $230KIndustry peers: median -176%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -91% of revenue this year, a -91% median across 8 years. Treating stock comp as the real expense it is (less $25M of SBC) leaves ($100M).
- Are earnings backed by cash? ($74M)Loss, and burning cashNet income ($66M) · cash from operations ($74M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.08×HarvestingCapex $230K ÷ depreciation $3M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 2 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $82M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 6.64×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $101M vs $205M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (8-yr record) · 7 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.07/share (latest year $-2.31), the averaged base the calculator's gate runs on, and book value is $7.53/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2018–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 1 of 8
What this means
Lost money in 7 year(s), look at what happened there before trusting the average.
- Operating margin −337% → −68% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about −337% early to −68% lately, median −123% — pricing power intact or improving.
- Worst year 2021 · −1641.3% op. margin
What this means
Operations went underwater in 2021, understand why before trusting the good years.
- How management talks about it Promotional
What this means
The record is compounding, but the filing leans on a promoter’s vocabulary rather than the per-share, return-on-capital terms an owner uses. The results back the talk here; the register is still worth noting.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
In its own filing Framed as a capability
The filing positions AI as something the company uses, not something it fears.
“High-resolution computed tomography (HRCT) lung scans analyzed using FDA 510(k)-cleared AI technology, revealed reductions in mucus burden in four of six Class I CF participants.”
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
Current assets$217M
- Cash & short-term investments$211M
- Receivables$1M
- Other current assets$4M
Current liabilities$34M
- Debt due within a year$61M
- Accounts payable$4M
Current ratio6.31×all current assets ÷ what's due · Graham looked for 2×
Quick ratio—inventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio6.15×strictest: cash alone against what's due
Working capital$183Mthe cushion left after near-term bills
Debt due this year vs. cash$61M due · $211M cash
covered by cash on hand, no refinancing forced · both figures from the Mar 31, 2026 balance sheet
Cash runway3.6 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago−93.0%the freshest read on whether the business is still growing
Current ratio, recent quarters3.8× → 6.3×
Deeper floors
Tangible book value$191Mequity stripped of goodwill & intangibles
Net current asset value$163MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$100M$24M of it operating leases
Deferred revenue$12Mcustomer cash collected before delivery; operating float
From the company's latest filing.
Management, ownership & pay
From the proxy: how much of the business the people running it own, and how they are paid.
- Stock-based compensation$25M
The slice of the business handed to employees in shares this year, 31% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Inverting the record
Invert: instead of why Arcturus Therapeutics Holdings Inc. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2018–2025.
1 of the 3 tests turned up something to look into; the other 2 came back clean.
- Look hereDid debt outgrow the business?$10M → $76M
Debt rose from $10M to $76M while owner earnings went from about ($24M) to ($52M): the borrowing grew and the earnings that would carry it are not there now. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.
And these came back clean
- Is it less profitable than it was?
- Did receivables and inventory outpace sales?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| SPRYARS Pharmaceuticals Inc. | $84M | — | -353.3% | -39% | -320% |
| ARCTArcturus Therapeutics Holdings Inc. | $82M | — | -107.8% | -71% | -65% |
| ADCTADC Therapeutics SA | $81M | 93% | -174.6% | — | -176% |
| ETONEton Pharmaceuticals Inc. | $80M | 60% | -6.8% | -108% | 2% |
| CTMXCytomX Therapeutics Inc. | $76M | — | -124.3% | -20% | -81% |
| OMEROmeros Corporation | $74M | 98% | -451.5% | -213% | -417% |
| ASMBAssembly Biosciences Inc. | $72M | — | -602.7% | -70% | -130% |
| VRDNViridian Therapeutics Inc. | $71M | 96% | -1815.9% | — | -1328% |
| Group median | — | — | -263.9% | -71% | -153% |
The price
What a price has to assume.
What the price implies
reverse-DCFArcturus Therapeutics Holdings Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
$
The assumptions
Revenue, delivered−25%/yr’20→’25
Enter a price to run it.
Owner earnings it must reach—
Margin the price demands—
Owner-earnings margin today−107%
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Cite: Owner Scorecard, "Arcturus Therapeutics Holdings Inc. (ARCT), the owner's record," https://ownerscorecard.com/c/ARCT, data as of 2026-07-09.
Manual order: ← ARCB its page in the Manual ARDT →
Industry order: ← AQST the Pharmaceuticals chapter ARDX →